HOME > COMMENTARY
COMMENTARY
-
Key Figures in Next Drug Pricing Reform Now All in Place, In What Direction Will They Go for Pro-Innovation Drive?
November 15, 2023
-
Predicting Clinical, Financial Impact of Hemophilia Gene Therapy in Japan
November 7, 2023
-
Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
-
With 2nd Strategy Penned, Can Japan Play Catch-Up with US & Europe in SaMD Push?
October 3, 2023
-
Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
-
Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
-
Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?
August 23, 2023
-
Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023
-
Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
-
Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
Will Bill to Amend Medical Infrastructure Law Accelerate Drug Discovery for Rare Diseases?
April 28, 2023
-
Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
-
FY2024 Pricing Reform Likely to Focus on “Balance” between Rewarding Innovation and Optimizing LLP Prices
February 6, 2023
-
LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
-
Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
-
Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
-
Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…